Saluda Medical

Saluda Medical is a private, commercial-stage medical device company developing a novel, data-driven approach to spinal cord stimulation. Its flagship Evoke® System utilizes proprietary ECAP-sensing technology to create a closed-loop therapy that automatically adjusts stimulation in real-time based on the patient's neural response, aiming for superior and more consistent pain relief. Backed by robust clinical evidence from the landmark double-blind EVOKE study, the company is positioned to challenge established SCS players by offering an objectively controlled therapy with demonstrated long-term outcomes. Saluda is leveraging its foundational sensing platform to potentially expand into new neuromodulation indications.

Proprietary Evoked Compound Action Potential (ECAP) sensing technology enabling closed-loop spinal cord stimulation. The system records the spinal cord's physiological response to each stimulation pulse and automatically adjusts therapy in real-time to maintain a consistent, personalized neural dose.

Saluda competes directly with major medical device companies in the SCS space, including Medtronic, Abbott, Boston Scientific, and Nevro. Its primary competitive differentiation is its closed-loop, ECAP-controlled therapy, which is supported by unique double-blind RCT data showing long-term superiority in pain relief and patient outcomes. It positions itself as a technology leader in objective, personalized neuromodulation.